European Pharmaceutical Review

FEBRUARY 8, 2023

Breyanzi will exhibit the largest compound annual growth rate (CAGR) at 30 percent, compared to Yescarta’s CAGR of 9 percent. Breyanzi is approved for DLBCL, and a label expansion is anticipated for expansions into marginal zone lymphoma (MZL) and mantle cell lymphoma (MCL) in 2026 and 2028, respectively. billion in 2031.

Labelling 94

Labelling Compounding 94

pharmaphorum

MARCH 14, 2022

Novel Compounds and Treatments for Pain: Opioids and the Alternatives. Million by 2026, growing at a CAGR of 4.40 % from 2019 to 2026. Sponsored by: CHDR. Conference Chairman: Richard Malamut, Chief Medical Officer, Collegium Pharmaceutical, Inc. The global Postoperative Pain Therapeutics Market was valued at USD 11.26

Compounding 52

Compounding Drug Development 52

pharmaphorum

JUNE 27, 2022

per share if Tazverik hits $250 million in annual sales in four consecutive quarters before the end of 2026, and $0.70 if the drug is cleared for the second-line FL inflation before 1 January, 2028. Ipsen’s CVR offer includes $0.30 The post Ipsen beefs up in oncology, buying US biopharma Epizyme appeared first on.

Compounding 110

Compounding 110

RX Note

FEBRUARY 4, 2024

Introduction In parallel with industrialization, the focus of pharmacists' practice has evolved from compounding and dispensing medications to the provision of professional services for patients. As experts in medicines, pharmacists can review complex medicine regimens and identify causes of problems and resolve them.

Community Pharmacies 52

Community Pharmacies Medical Records Compounding Diabetes 52

pharmaphorum

JUNE 2, 2022

By 2026, the report predicts that each of the top 10 selling orphan drugs will earn between $3 billion and $13 billion. The report estimates that the orphan drug market will grow twice as fast as the non-orphan market, with a 2021 to 2026 compound annual growth rate of 12%.

Compounding 52

Compounding Pharmaceutical Companies Pharmaceutical Companies Drug Pricing 52

pharmaphorum

JANUARY 18, 2023

AI-based medical imaging was a market worth more than $400 million in 2021, according to figures cited by Bayer, and is expected to have a compound annual growth rate (CAGR) of more than 26% between 2020 to 2026, driving its value to around $1.36

Compounding 59

Compounding 59

pharmaphorum

APRIL 24, 2022

In a statement, the drugmaker said “we stand by the safety of aducanumab, and we look forward to upcoming data readouts to continue to provide important information on the science of this new class of compound.”

Compounding 52

Compounding 52

Pharmaceutical Technology

JULY 26, 2022

The three major markets (3MM: the US, Germany and the UK) will increase in market size from $128.35m last year to $188.35m in 2031, at a compound annual growth rate (CAGR) of 3.9%. This sales growth will be in line with a steadily increasing disease prevalence and the entrance of novel agents into the market.

Compounding 122

Compounding Labelling 122

LifeProNow

MARCH 27, 2023

The estimated compounded annual growth rate is more than 26 percent reaching $1.36 billion in sales by 2026. Bayer has exclusive worldwide marketing rights for this product including the U.S. The medical imaging AI market is the fastest growing segment within the global radiology industry.

Bioethics 130

Bioethics Compounding Diabetes 130

pharmaphorum

JANUARY 10, 2023

Approximately 30% of global data volume is generated by the healthcare industry and it will continue to expand with a compound annual growth rate predicted to reach 36% by 2025, according to research by RBC Capital Markets. billion by 2026, according to research by the Business Research Company. billion in 2021 to $9.23

Compounding 98

Compounding Communication Pharmaceutical Companies Pharmaceutical Companies 98

Express Pharma

DECEMBER 29, 2023

Israel’s pharma market, valued at about $5 billion, is projected to grow at a five-year compound annual growth rate (CAGR) of 4.2 per cent up to 2026. per cent up to 2026. Colombia, the third-largest pharma market in South America is projected to grow at a five-year CAGR of 3.1

Compounding 110

Compounding 110

Pharmaceutical Technology

JANUARY 10, 2023

billion in 2029, with drug sales almost doubling at a compound annual growth rate (CAGR) of 11.5%. GlobalData expects that the T2D market will see significant growth from 2019–29, with the 9MM having a total of $45.9 billion in sales in 2019, increasing to $136.2

Biosimilars 52

Biosimilars Labelling Diabetes Compounding 52

PharmaShots

FEBRUARY 22, 2023

In the US, Trulicity is protected by a compound patent (2027) and by biologics data protection (2026). Hence, it needs to protect its patent as Trulicity patents are very vital to the company’s business as a whole.

Diabetes 64

Diabetes Compounding Dosage Communication 64

European Pharmaceutical Review

JUNE 28, 2022

billion by 2026, achieving a compound annual growth rate (CAGR) of 13.2 percent CAGR between 2022 and 2026. According to recent market research , the global market for biopharmaceutical bioseparation systems, estimated to value $13 billion in 2022, is projected to grow to $19.6

Dosage 99

Dosage Compounding Drug Development 99

FDA Law Blog: Biosimilars

DECEMBER 3, 2023

On November 17th, CMS issued its final guidance on the Discount Program in which it responded to public comments and provided updated guidance for the Discount Program for 2025 and 2026. The Discount Program is similar to the CGDP with respect to several requirements and operational processes, and CMS will implement it in a similar manner.

Labelling 105

Labelling Drug Pricing Compounding Payment Processing 105